Hysingla Brand Logo

Site Map

  • Home
  • Before You Prescribe
  • Key Attributes
  • 24-Hour Delivery
  • Abuse-Deterrent Properties (ADP)
    • Abuse-Deterrence Labeling
    • RESISTEC™
    • Categories of Studies
    • In Vitro Testing
    • Intranasal Abuse Potential Study
    • Oral Abuse Potential Study
    • Addiction, Abuse, Misuse, & Diversion/REMS
  • Dosing
    • Considerations for Prescribing
    • Initiation of Therapy
    • Conversion From Oral IR Hydrocodone/APAP
    • Conversion From Other Opioids
    • Reassess Continually
    • Titration & Maintenance
    • Safe Reduction or Discontinuation
    • Clinically Significant Drug Interactions
  • Clinical Data
    • Overview
    • Pivotal Trial: Design
    • Pivotal Trial: Efficacy
    • Pivotal Trial: Adverse Reactions
    • Pivotal Trial: Additional Data
  • Savings
  • Resources
    • Overview
    • REMS
Down arrow
  • PurduePharma.com
  • Full Prescribing Information
  • Report an Adverse Event
  • Product Quality Complaint
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
  • Abuse-Deterrence Labeling
  • Opioid Analgesics REMS
  • Do Not Sell My Information
Purdue Logo

©2023 Purdue Pharma L.P., Stamford, CT 06901-3431. Intended for residents of the United States only. Purdue, as used in this site, refers to Purdue Pharma L.P., a company in a network of independent associated companies.

MR-08208 01/2023

@PurduePharma
When you access any of our websites, related other parties’ websites, mobile applications, or any electronic service, we may use cookies and other technologies to automatically collect information regarding you and your device to assess user activity and preferences. We may also use third-party analytic tools to assist with the collection of information including, but not limited to, Google Analytics. By using this site, you agree to our use of these technologies in accordance with our Privacy Policy.